Cargando…
Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic
Autores principales: | Pfeiler, Georg, DeMichele, Angela, Dueck, Amylou C, Fesl, Christian, Gnant, Michael, Mayer, Erica L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803349/ https://www.ncbi.nlm.nih.gov/pubmed/35114114 http://dx.doi.org/10.1016/S1470-2045(21)00708-7 |
Ejemplares similares
-
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
por: Grinshpun, Albert, et al.
Publicado: (2023) -
Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors
por: McCartney, Amelia, et al.
Publicado: (2020) -
Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors? A Word of Cautiousness. Comment on Marcianò et al. Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association. Int. J. Environ. Res. Public Health 2020, 17, 9509
por: Fusco, Vittorio, et al.
Publicado: (2021) -
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
por: Gnant, M, et al.
Publicado: (2013) -
More is not always better—what can be learned from the D-CARE trial
por: Pfeiler, Georg, et al.
Publicado: (2020)